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The MARS-CT project aims to develop novel x-ray imaging systems based on state of 
the art spectral x-ray detectors from CERN (European Centre for Nuclear Research). 
The MARS-CT system being developed provides energy-specific attenuation of 
tissue, in addition to conventional information.  
 
Dual energy systems have demonstrated clinical benefit in a wide range of areas such 
as cancer imaging (including breast and bowel) and vascular imaging (e.g. heart 
disease). These dual energy systems are based on two x-ray beams at different 
energies. Unfortunately this dual beam approach increases the x-ray dose to the 
patient and this has slowed the adoption of the technology. With the MARS approach 
we use a single x-ray beam with a spectral detector. This means not only no extra 
dose to the patient but also multiple energy measurements. The extra energy 
information provides enhanced differentiation between tissue types such as bone, 
muscle, fat and contrast agents. Thus we are able to provide more information to the 
radiologist, enabling better diagnosis, and without the drawbacks of the dual source 
approach. 
 
The MARS (Medipix All Resolution System) is based on CERN’s Medipix x-ray 
detector. Collaborations of more than 18 universities from around the world have 
developed the technology over 12 years. Medipix is a photon processing detector, that 
is, it records the properties of an x-ray beam on a photon by photon basis with 
virtually no detector noise. In particular, each pixel of the Medipix detector has the 
electronics to measure and record the energy of each photon. Research by us, our 
partners, and others have demonstrated that photon processing detectors give an 
increased signal-to-noise of between 5-100 times. This promises a significantly 
lowered radiation dose to the patient. 
 
The project has developed small animal and pathology scanners based on the 
technology. These machines provide a medium cost device, enabling pre-clinical 
researchers to investigate the technology and confirm clinical benefit. To date, 
medical researchers at the University of Otago Christchurch and the University of 
Canterbury have been successfully using the technology. We are now forging research 
relationships with the radiology department of Johns Hopkins University and the 
small animal imaging lab of the Mayo Clinic, Rochester, both of whom wish to use 
MARS-CT scanners for their pre-clinical research. 
 
In future we plan to develop the technology further so that a body part scanner can be 
constructed, enabling clinical trials of the technology. Currently we plan to develop a 
MARS breast CT unit. Following this, we intend to develop detector assemblies that 
can be used in the full body CT scanners,  that are used in virtually all modern 
hospitals. 
